Appropriate hematocrit levels of erythropoietin supplementary therapy in end-stage renal failure complicated by coronary artery disease

Canadian Journal of Cardiology

Volumn 13, Issue 8, 1997, Pages 747-753

  Nagao, Kazuhiko ^a,b   Tsuchihashi, Kazufumi ^a   Ura, Nobuyuki ^a   Nakata, Tomoaki ^a   Shimamoto, Kazuaki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

Angina pectoris; Hematocrit; Recombinant human erythropoietin; Renal anemia

Indexed keywords

EPODIN; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DEATH; DISEASE SEVERITY; EXERCISE; EXERCISE ELECTROCARDIOGRAPHY; EXERCISE TOLERANCE; FEMALE; HEART INFARCTION; HEMATOCRIT; HUMAN; HYPERTENSION; JAPAN; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; REST;

ADULT; AGED; ANEMIA; CORONARY DISEASE; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMATOCRIT; HUMANS; INFORMED CONSENT; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 0030884075     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Wizemann V, Kaufmann J, Kramer W. Effect of erythropoietin on ischemia tolerance in anemic hemodialysis patients with confirmed coronary artery disease. Nephron 1992;62:161-5.
2. Braumann KM, Nonnast-Daniel B, Boning D, Bocker A, Frei U. Improved physical performance after treatment of renal anemia with recombinant erythropoietin. Nephron 1991;58:129-34.
3. Morrow CE, Schwartz JS, Sutherland DE, et al. Predictive value of thallium stress testing for coronary and cardiovascular events in uremic diabetic patients before renal transplantation. Am J Surg 1983;146:331-5.
4. Roig E, Berui A, Castaner A, Magrina J, Sanz G, Navarro-Lopez F. Disabling angina pectoris with normal coronary arteries in patients undergoing long-term hemodialysis. Am J Med 1981;71:431-4.
5. Rostand SG, Kirk KA, Rutsky EA. Dialysis-associated ischemic heart disease insights from coronary angiography. Kidney Int 1984;25:653-9.
6. Marshall WG Jr, Rossi NN, Meng RL, Wedige-Stecher T. Coronary artery bypass grafting in dialysis patients. Ann Thorac Surg 1986;42:S12-5.
7. Kahn JK, Rutherford BD, McConahay DR, Johnson WL, Giorgi LV, Hartzler GO, Short- and long-term out-come of percutaneous transluminal angioplasty in chronic dialysis patients. Am Heart J 1990;119:484-9.
8. Winearles CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Gotes PM. Effect of human erythropoietin derived from recombinant DNA on the anemia of patients maintenance by chronic hemodialysis. Lancet 1986;ii:1175-8.
9. MacDowgall IC, Lewis ND, Saunders RD, Fox KAA, Coles GA, Williams JD. Long-term cardiorespiratory effects of amelioration of renal anemia by erythropoietin. Lancet 1990;335:489-93.
10. Fellner SK, Lang RM, Neumann A, Korcarz C, Borow KM. Cardiovascular consequences of the correction of anemia in renal failure with erythropoietin. Kidney Int 1993;44:1309-15.
11. Maver G, Thum J, Cada EM, Stummvoll HK, Graf H, Working capacity is increased following recombinant human erythropoietin treatment. Kidney Int 1988;34:525-8.
12. Low-Friedrich I, Grutzmacher P, Marz W, Bergmann M, Schoeppe W. Therapy with recombinant human erythropoietin reduces cardiac size and improves heart function in chronic hemodialyzed patients. Am J Nephrol 1991;11:54-60.
13. Hase H, Imamura Y, Nakamura R, Inishi Y, Machii K, Yamaguchi T. Effect of rHuEPO therapy on exercise capacity in hemodialysis patients with coronary artery disease. Jpn Circ J 1993;57:131-7.
14. Imamura Y, Hase H. [Effect of recombinant human erythropoietin (rEPO) on angina pectoris patients with chronic maintenance hemodialysis.] Jpn J Nephrol 1991;33:65-70.
15. Nakata T, Noto T, Uno K, et al. Quantification of area and percentage of infarcted myocardium by single photon emission computed tomography with thallium-201: A comparison with serial serum CK-MB measurements. Ann Nucl Med 1989;3:1-8.
16. Austen WG, Edwards JE, Frye RL, et al. AHA Committee Report: A reporting system on patients evaluated for coronary artery disease. Report of the ad hoc committee for grading of coronary heart disease. Council on Cardiovascular Surgery, American Heart Association. Circulation 1975:51;7-40.
17. Leaman DM, Brower RW, Meester GT, Sermys P, Van Den Brand M. Coronary artery atherosclerosis: severity of the disease, severity of angina pectoris and compromised left ventricular function. Circulation 1981:63;285-92.
18. The American College of Sports Medicine. Guide-lines for Exercise Testing and Prescription, 4th edn. Philadelphia: Lea & Febiger, 1991:61-2.
19. Bauman KM, Nonnst-Daniel B, Boning D, Bocker A, Frei U. Improved physical performance after treatment of renal anemia with recombinant human erythropoietin Nephron 1991;58:129-34.
20. Lundin AP, Akerman MJH, Chesler RM, Delano BG, Stein RA, Friedman EA. Exercise in hemodialysis patients after treatment with recombinant human erythropoietin. Nephron 1991;58:813-9.
21. London GM, Zins B, Pamier B, et al. Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. Kidney Int 1989;36:878-82.
22. Raine HE. Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: Implications of erythropoietin therapy. Lancet 1988;i:97-9.
23. Baer RW, Vlahakes GJ, Uhlig PN, Huffman JI. Maximum myocardial oxygen transport during anemia and polycythemia in dogs. Am J Physiol 1987;252:H1086-94.